Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Noble Financial issued their Q2 2025 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a note issued to investors on Monday, May 19th. Noble Financial analyst R. Leboyer expects that the company will earn ($0.22) per share for the quarter. The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.81) per share. Noble Financial also issued estimates for Eledon Pharmaceuticals' Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.86) EPS.
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.20.
Several other brokerages have also recently commented on ELDN. Wall Street Zen raised Eledon Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Thursday. Guggenheim began coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They set a "buy" rating and a $9.00 target price on the stock.
Read Our Latest Report on ELDN
Eledon Pharmaceuticals Price Performance
ELDN traded up $0.03 on Wednesday, reaching $3.05. 175,430 shares of the company traded hands, compared to its average volume of 273,037. The stock's 50 day moving average price is $3.12 and its 200-day moving average price is $3.88. The company has a market cap of $182.64 million, a price-to-earnings ratio of -1.52 and a beta of 0.08. Eledon Pharmaceuticals has a 52-week low of $2.30 and a 52-week high of $5.54.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. RA Capital Management L.P. acquired a new position in shares of Eledon Pharmaceuticals in the 4th quarter valued at $14,693,000. Sphera Funds Management LTD. boosted its holdings in shares of Eledon Pharmaceuticals by 96.7% in the 4th quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company's stock worth $10,513,000 after acquiring an additional 1,254,298 shares in the last quarter. First Light Asset Management LLC bought a new position in Eledon Pharmaceuticals in the 4th quarter valued at $9,595,000. Blue Owl Capital Holdings LP acquired a new stake in shares of Eledon Pharmaceuticals in the fourth quarter valued at $8,075,000. Finally, Woodline Partners LP grew its stake in shares of Eledon Pharmaceuticals by 98.3% during the fourth quarter. Woodline Partners LP now owns 1,671,822 shares of the company's stock valued at $6,888,000 after purchasing an additional 828,930 shares during the last quarter. 56.77% of the stock is currently owned by institutional investors and hedge funds.
About Eledon Pharmaceuticals
(
Get Free Report)
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Further Reading
Before you consider Eledon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.
While Eledon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
